ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
Exclusive license agreement with ALK-Abelló to commercialize neffy ® in Europe, Canada and certain other geographies; ARS Pharma to receive $145 million in upfront payment with total deal consideration of up to $465 million plus double-digit royalties Well-capitalized with $349.
Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Building on its collaboration with Enable Injections, Serina presented a case study at the 14th Annual Injectables Summit in Boston, MA, detailing the combination of Serina’s lead candidate, SER-252 (POZ-apomorphine),
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class (i) targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended September 30,
Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results
Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones Conference call today at 4:30 p.
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Detailed price information for Seres Therapeutics Inc (MCRB-Q) from The Globe and Mail including charting and trades.
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call
LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective ...
Yahoo Finance3d
Vivos Therapeutics, Inc. (VVOS)
Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company specializing in the development and commercialization of ...
ETF Daily News1mon
Critical Survey: Vivos Therapeutics (NASDAQ:VVOS) & Iradimed (NASDAQ:IRMD)
26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 92.3% of Iradimed shares are owned by institutional investors. 9.6% of Vivos Therapeutics shares are ...
Mena FN1mon
Tinygemsbreaks Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct Offering
(MENAFN- Investor Brand Network) Vivos Therapeutics (NASDAQ: VVOS) , a leading medical device and technology company specializing in the development and commercialization of highly effective ...
Yahoo Finance1mon
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
LITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company ...
ADVFN1mon
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly ...